Abstract:Abstract Background Immune checkpoint inhibitor associated pneumonia(CIP) is the most dangerous adverse reaction of immunecheckpoint inhibitors. Howerer,research on the factors affecting its severity is limited. Methods This retrospective study analyzed 2673 patients who underwent immune checkpoint inhibitor(ICI)treatment at the First Affiliated Hospital of Zhejiang University between 2019 and 2023. Of these, 106 cases of immune checkpoint inhibitor associated pneumonia(CIP) were identified, all of which were associated with lung cancer. The clinical manifestations and diagnostic and therapeutic approaches used for these 106 patients were summarized. The patients were also classified into four types based on clinical characteristics and imaging findings, and a detailed analysis was conducted. Results It was found that immune checkpoint inhibitor associated pneumonia(CIP) occurred at a median of 5.17 months (95%CI 4.61‒5.72) after the start of immune checkpoint inhibitor(ICI) therapy.Grade 4 was usually the earliest to be identified and had the poorest prognosis, with a median onset of 2.47 months after treatment (95%CI 0, 5.12 months), an incidence rate of 4.7%, a median progression-free survival (mPFS) of 3.83 months, and a median overall survival (mOS) of 4.03 months. The PFS curves for Grades 1–2 and Grades 3–4 CIP showed separation but without statistical significance (mPFS 8.47 m vs. 6.50 m, HR = 3.36, log-rank P = 0.07), while the difference in OS was significant OS (mOS 23.15 m vs. 11.20 m, HR = 8.97, log-rank P = 0.003). Multivariate logistic regression showed that forced vital capacity (FVC) was the only predictive factor linked to 3–4 grades occurrence (OR = 1.00, 95% CI 0.01–0.80, P = 0.03), with decreased forced vital capacity (FVC) an independent risk factor for the grade 3–4 CIP (OR = 1.00, 95% CI 0.01–0.80, P = 0.03). Conclusions Forced vital capacity(FVC) was observed to be the only independent risk factor for grade 3–4 immune checkpoint inhibitor associated pneumonia(CIP), reminding us of the importance of assessing baseline pulmonary function testing before immune checkpoint inhibitor use. In addition to forced vital capacity(FVC), active monitoring of radiological examinations and clinical manifestations remains meaningful.

Advances in CT Features and Radiomics of Checkpoint Inhibitor-Related Pneumonitis: A Short Review

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis

Delta Radiomics Model for the Prediction of Progression-Free Survival Time in Advanced Non-Small-cell Lung Cancer Patients after Immunotherapy.

Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management

Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer

Radiomics Biomarkers to Predict Checkpoint Inhibitor Pneumonitis in Non-small Cell Lung Cancer

High-Resolution CT Patterns of Anti-PD1 Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis

Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis

Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Clinical Types of Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients: a Multicenter Experience.

Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning

Clinical Features and Determinants of Disease Severity of Immune Checkpoint Inhibitor-Related Pneumonitis: A Retrospective Study

Identifying Risk Factors and Biomarkers for Severe CIP in Lung Cancer Patients- a Retrospective Case Series Study.

Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis

Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)